Table-II.
Frequency and percentage of prior exposure of antimicrobial agents in patients with MDR ACB VAP compared to susceptible ACB VAP; crosstabs Chi square analysis for odds ratio of developing MDR strain infection. Bold signifies p<0.05.
| Variables | MDR Acinetobacter baumannii n = 69 | Susceptible Acinetobacter baumannii n = 67 | p-value | OR (95% CI) |
|---|---|---|---|---|
| Classes of antimicrobials (freq(%)) | ||||
| Penicillins | 23 (33.3) | 15 (22.4) | 0.155 | 1.733 (0.269-1.236) |
| Cephalosporins | 57 (80.6) | 46 (68.3) | 0.016 | 4.491 (1.206-16.721) |
| Macrolides | 16 (23.2) | 21 (31.3) | 0.285 | 0.661 (0.309-1.415) |
| Fluoroquinolones | 4 (9.0) | 6 (5.8) | 0.481 | 0.626 (0.168-2.325) |
| Aminoglycosides | 5 (7.2) | 10 (14.9) | 0.153 | 0.445 (0.144-1.380) |
| Glycopeptides | 10 (14.5) | 5 (7.5) | 0.191 | 2.102 (0.678-6.514) |
| Carbapenems | 46 (66.7) | 7 (10.4) | <0.001 | 17.143 (8.769-43.412) |
| β-lactam/β-lactamase inhibitors, penicillins | 37 (53.6) | 32 (47.8) | 0.494 | 1.265 (0.645-2.480) |
| Other β-lactam/β-lactamase inhibitors | 12 (17.4) | 9 (14.5) | 0.736 | 0.867 (0.377-1.993) |
| Imidazoles | 16 (23.2) | 11 (16.4) | 0.322 | 1.537 (0.654-3.612) |